Advertisement
Advertisement
U.S. Markets close in 9 mins
Advertisement
Advertisement
Advertisement
Advertisement

MannKind Corporation (MNKD)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
3.5300+0.3400 (+10.66%)
As of 03:51PM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close3.1900
Open3.2000
Bid3.4900 x 1800
Ask3.5000 x 4000
Day's Range3.2000 - 3.5750
52 Week Range2.4900 - 5.5300
Volume6,047,950
Avg. Volume3,554,057
Market Cap886.934M
Beta (5Y Monthly)1.96
PE Ratio (TTM)N/A
EPS (TTM)-0.3230
Earnings DateFeb 23, 2022 - Feb 28, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.00
  • GlobeNewswire

    MannKind Corporation to Ring the Nasdaq Stock Market Opening Bell

    WESTLAKE VILLAGE, Calif. and DANBURY, Conn., May 19, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer, Michael Castagna, PharmD, will ring the opening bell at the Nasdaq stock exchange on Monday, May 23, 2022 at 9:30 am ET at the Nasdaq MarketSite at Times Square. The ceremony will begin at a

  • GlobeNewswire

    MannKind Corporation Announces Agreement to Acquire V-Go® Insulin Delivery Device From Zealand Pharma

    V-Go® acquired by MannKind Corporation MannKind Corporation announced today an agreement to acquired V-Go® insulin delivery device from Zealand Pharma. V-Go is a once-daily insulin delivery device that strengthens MannKind’s commitment to offering innovative mealtime diabetes solutions. The once-daily insulin delivery device strengthens MannKind’s commitment to offering innovative mealtime diabetes solutions DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- MannKind C

  • GlobeNewswire

    MannKind Corporation Participating at Upcoming Conferences

    WESTLAKE VILLAGE, Calif. and DANBURY, Conn., May 09, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that it will be participating at upcoming conferences. Presenting from the Company will be its Chief Executive Officer, Michael Castagna, PharmD. 2022 RBC Capital Markets Global Healthcare Conference – Tuesday, May 17, 2022

Advertisement
Advertisement